Leerink Partners analyst David Risinger has reiterated their bullish stance on ROIV stock, giving a Buy rating yesterday. David Risinger has ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Q2 2024 Earnings Call Transcript November 12, 2024 Operator: Good day and thank you for standing by. Welcome to the Roivant ...

In this update, I'll focus on Organon's Q3 2024 results, earnings adjustments and segment performance, as well as the ...

Roivant Sciences Ltd (ROIV) showcases robust financial health with $5.4 billion in cash and no debt, while navigating competitive pressures and strategic opportunities.

The company's FDA-approved drug Sofdra is the first for the common and embarrassing condition of excessive sweating.

The Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for tapinarof cream, 1% in the treatment of atopic dermatitis in adults and ...

Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...

Organon , a global healthcare company with a mission to improve the health of women throughout their lives, today announced that the U.S. Food and Drug Administration (FDA) extended by three months ...

DelveInsight's 'Exosomes Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and ...

An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug ...